4.6 Review

Microsatellite instability assessment is instrumental for Predictive, Preventive and Personalised Medicine: status quo and outlook

Journal

EPMA JOURNAL
Volume 14, Issue 1, Pages 143-165

Publisher

SPRINGER INT PUBL AG
DOI: 10.1007/s13167-023-00312-w

Keywords

Microsatellite instability; Cancer; Screening; Massively parallel sequencing; Liquid biopsy; Patient stratification; Predictive Preventive Personalised Medicine (PPPM; 3PM)

Ask authors/readers for more resources

Microsatellite instability (MSI) is a form of genomic alteration caused by the failure of a post-replicative DNA mismatch repair (MMR) system in a class of tandem repeats (TRs) called microsatellites (MSs) or short tandem repeats (STRs). Traditional strategies for determining MSI events are low-throughput procedures that require assessment of both tumor and healthy samples. However, recent large-scale pan-tumor studies have shown the potential of massively parallel sequencing (MPS) in detecting MSI.
A form of genomic alteration called microsatellite instability (MSI) occurs in a class of tandem repeats (TRs) called microsatellites (MSs) or short tandem repeats (STRs) due to the failure of a post-replicative DNA mismatch repair (MMR) system. Traditionally, the strategies for determining MSI events have been low-throughput procedures that typically require assessment of tumours as well as healthy samples. On the other hand, recent large-scale pan-tumour studies have consistently highlighted the potential of massively parallel sequencing (MPS) on the MSI scale. As a result of recent innovations, minimally invasive methods show a high potential to be integrated into the clinical routine and delivery of adapted medical care to all patients. Along with advances in sequencing technologies and their ever-increasing cost-effectiveness, they may bring about a new era of Predictive, Preventive and Personalised Medicine (3PM). In this paper, we offered a comprehensive analysis of high-throughput strategies and computational tools for the calling and assessment of MSI events, including whole-genome, whole-exome and targeted sequencing approaches. We also discussed in detail the detection of MSI status by current MPS blood-based methods and we hypothesised how they may contribute to the shift from conventional medicine to predictive diagnosis, targeted prevention and personalised medical services. Increasing the efficacy of patient stratification based on MSI status is crucial for tailored decision-making. Contextually, this paper highlights drawbacks both at the technical level and those embedded deeper in cellular/molecular processes and future applications in routine clinical testing.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available